AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16439867 — intervention group
Group type: COMPARATOR
Intervention: Standard interferon alfa (IFN) with ribavirin (R)
Number of subjects: 108
Study 16439867 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 108
Study 12921983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 45
Study 12921983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10711438 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 52‐Fr Maloney dilation
Number of subjects: 26
Study 10711438 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic biopsy of Schatzki's ring (four quadrant biopsy)
Number of subjects: 26
Study 9373419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for psychosis, individualised, lasting nine months
Number of subjects: 60
Study 9373419 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 60
Study 1610419 — intervention group
Group type: EXPERIMENTAL
Intervention: solution gel (1% diclofenac)
Number of subjects: 12
Study 1610419 — intervention group
Group type: COMPARATOR
Intervention: emulsion gel (1% diclofenac)
Number of subjects: 12
Study 3859953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin gel for cervical priming
Number of subjects: 64
Study 3859953 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic prostaglandin gel for labour induction
Number of subjects: 64
Study 3859953 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 64
Study 3859953 — intervention group
Group type: COMPARATOR
Intervention: Systemic administration of PG
Number of subjects: 64
Study 31135178 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 59
Study 31135178 — intervention group
Group type: COMPARATOR
Intervention: Child Life (CL) distraction
Number of subjects: 59
Study 31135178 — intervention group
Group type: COMPARATOR
Intervention: Television (TV) distraction
Number of subjects: 59
Study 28230324 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based diet (FD)
Number of subjects: 60
Study 28230324 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-replacement plan (MRP)
Number of subjects: 60
Study 28230324 — intervention group
Group type: COMPARATOR
Intervention: Both diets (FD and MRP)
Number of subjects: 60
Study 25891304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg)
Number of subjects: 142
Study 25891304 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab (3 mg/kg) + placebo
Number of subjects: 142
Study 25891304 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab + ipilimumab
Number of subjects: 142
Study 25891304 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab monotherapy
Number of subjects: 142
Study 23902407 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri ATCC 55730 (1 × 10(8) CFU)
Number of subjects: 232
Study 21211053 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program involving an in-service for centre staff, distribution of educational materials to parents, a parent workshop demonstrating restraint use, subsidised restraints for parents in need, and vouchers for a free restraint checking service.
Number of subjects: 28
Study 21211053 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 28
Study 19953806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect instruction with 'The Smiling Robot' and periodic reinforcement
Number of subjects: 40
Study 19953806 — intervention group
Group type: COMPARATOR
Intervention: Indirect instruction with 'The Smiling Robot' without periodic reinforcement
Number of subjects: 40
Study 16455814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 or 100 mg) during hypoxic exercise
Number of subjects: 10
Study 16455814 — intervention group
Group type: COMPARATOR
Intervention: Placebo during hypoxic exercise
Number of subjects: 10
Study 15057252 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of ECG LVH (defined as a >/=25% decrease in Cornell product)
Number of subjects: 584
Study 15057252 — intervention group
Group type: EXPERIMENTAL
Intervention: No significant change in ECG LVH (defined as a <25% decrease)
Number of subjects: 584
Study 15057252 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of ECG LVH (defined as an increase)
Number of subjects: 584
Study 15057252 — intervention group
Group type: COMPARATOR
Intervention: Regression of ECG LVH
Number of subjects: 584
Study 15057252 — intervention group
Group type: COMPARATOR
Intervention: No significant decrease in ECG LVH
Number of subjects: 584
Study 15057252 — intervention group
Group type: COMPARATOR
Intervention: Progression of ECG LVH
Number of subjects: 584
Study 12495832 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in sodium intake (100 mmol/24-hour)
Number of subjects: 873
Study 12495832 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in potassium intake (50 mmol/24-hour)
Number of subjects: 873
Study 9843861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 9843861 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (N)
Number of subjects: 10
Study 7867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg.kg‐1 administered into the pulmonary artery
Number of subjects: 120
Study 7867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg.kg‐1 administered into the right atrium
Number of subjects: 120
Study 7867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg.kg‐1 administered into a peripheral vein
Number of subjects: 120
Study 7867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium into the pulmonary artery
Number of subjects: 120
Study 7867112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium into the right atrium
Number of subjects: 120
Study 2474049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (20 ml d‐1 for 6 weeks)
Number of subjects: 18
Study 2474049 — intervention group
Group type: COMPARATOR
Intervention: Control (no cod liver oil)
Number of subjects: 18
Study 950801 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone and cyclophosphamide combined
Number of subjects: 39
Study 950801 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 39
Study 31285784 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day alpha-lipoic acid (ALA)
Number of subjects: 135
Study 31285784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 31285784 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 135
Study 28552830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to improve communication between clinicians and families of critically ill patients
Number of subjects: 181
Study 26500082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 g/d EPA + DHA
Number of subjects: 20
Study 26500082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/d EPA + DHA
Number of subjects: 20
Study 26500082 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/d EPA + DHA
Number of subjects: 20
Study 22885882 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic mixture (Probinul, 5 g bid)
Number of subjects: 64
Study 22885882 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 64
Study 21477675 — intervention group
Group type: EXPERIMENTAL
Intervention: TDV-TDV-TDV group (three TDV vaccinations at months 0, 3.5, and 12)
Number of subjects: 0
Study 21477675 — intervention group
Group type: COMPARATOR
Intervention: TyVi-TDV-TDV group (licensed typhoid vaccination at month 0 and TDV at months 3.5 and 12)
Number of subjects: 0
Study 19235738 — intervention group
Group type: EXPERIMENTAL
Intervention: Candy Smell Test (CST, 23 aromatized sorbitol candies)
Number of subjects: 353
Study 19235738 — intervention group
Group type: COMPARATOR
Intervention: Sniffin' Sticks test
Number of subjects: 353
Study 16239279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalosis (NaHCO3, 0.3 g kg(‐1))
Number of subjects: 9
Study 16239279 — intervention group
Group type: COMPARATOR
Intervention: Control (CaCO3)
Number of subjects: 9
Study 15523557 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal-based dentifrice
Number of subjects: 40
Study 15523557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11716995 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone (Livial, Organon)
Number of subjects: 20
Study 11716995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mg lactose)
Number of subjects: 20
Study 9068152 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-suit condition
Number of subjects: 13
Study 9068152 — intervention group
Group type: COMPARATOR
Intervention: Bathing-suit condition
Number of subjects: 13
Study 7711419 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily) from days 1-24
Number of subjects: 7
Study 7711419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg daily) from days 11-21
Number of subjects: 7
Study 7711419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg single dose) on day 43
Number of subjects: 7
Study 3415885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 3 or 4 ml
Number of subjects: 28
Study 3415885 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine 2 or 3 ml
Number of subjects: 28
Study 3415885 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine 2 ml
Number of subjects: 28
Study 3415885 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine 1.3 ml
Number of subjects: 28
Study 3415885 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dose of both solutions
Number of subjects: 28
Study 3415885 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-20/22.5 mg doses
Number of subjects: 28
Study 30552747 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 48
Study 30552747 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support group
Number of subjects: 48
Study 30552747 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 48
Study 28540538 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Promotion (HP) program
Number of subjects: 32
Study 28540538 — intervention group
Group type: COMPARATOR
Intervention: Frailty Intervention (FI)
Number of subjects: 32
Study 24077970 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence questionnaire asking about specific antiretroviral medication
Number of subjects: 6836
Study 24077970 — intervention group
Group type: COMPARATOR
Intervention: Adherence questionnaire asking about HIV medicines as a group
Number of subjects: 6836
Study 22244645 — intervention group
Group type: EXPERIMENTAL
Intervention: iRoot SP
Number of subjects: 80
Study 22244645 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 80
Study 22244645 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany
Number of subjects: 80
Study 22244645 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex
Number of subjects: 80
Study 22244645 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist condition
Number of subjects: 80
Study 22244645 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet condition
Number of subjects: 80
Study 18037080 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414
Number of subjects: 3994
Study 18037080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3994
Study 16286437 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium at a target dose of 750 mg/day (mean dose 800 mg/day) for 6 weeks
Number of subjects: 153
Study 16286437 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 153
Study 12402728 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ondansetron 100 micrograms kg‐1 i.v.
Number of subjects: 150
Study 12402728 — intervention group
Group type: COMPARATOR
Intervention: Early symptomatic treatment with placebo
Number of subjects: 150
Study 10549927 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor IX complex concentrate (FIXCC)
Number of subjects: 13
Study 10549927 — intervention group
Group type: COMPARATOR
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 13
Study 10549927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FFP and FIXCC)
Number of subjects: 13
Study 7562235 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc picolinate
Number of subjects: 0
Study 7562235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2360063 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 0
Study 2360063 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 0
Study 2360063 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 0
Study 6107409 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy (zinc chloride added to the dialysate for 6 weeks)
Number of subjects: 14
Study 6107409 — intervention group
Group type: COMPARATOR
Intervention: Placebo (added to the dialysate)
Number of subjects: 14
Study 6107409 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 14
Study 6107409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31050279 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 143
Study 31050279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 28251935 — intervention group
Group type: EXPERIMENTAL
Intervention: SIPsmartER intervention group
Number of subjects: 292
Study 28251935 — intervention group
Group type: COMPARATOR
Intervention: MoveMore control group
Number of subjects: 292
Study 28410176 — intervention group
Group type: EXPERIMENTAL
Intervention: SunProtect educational program delivered through a touch-screen tablet to 84 participants.
Number of subjects: 170
Study 28410176 — intervention group
Group type: EXPERIMENTAL
Intervention: SunProtect educational program delivered through a touch-screen tablet.
Number of subjects: 170
Study 23645393 — intervention group
Group type: EXPERIMENTAL
Intervention: 12W endovenous laser ablation (intermittent laser withdrawal)
Number of subjects: 76
Study 23645393 — intervention group
Group type: EXPERIMENTAL
Intervention: 14W endovenous laser ablation (continuous laser withdrawal)
Number of subjects: 76
Study 21733215 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioural intervention (overcoming anorexia online) with limited clinician supportive guidance
Number of subjects: 64
Study 21733215 — intervention group
Group type: COMPARATOR
Intervention: Usual support from the UK patient and carer organization Beat
Number of subjects: 64
Study 21733215 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioural intervention
Number of subjects: 64
Study 19690352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve fibre detection in endometrial biopsy
Number of subjects: 99
Study 17920552 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel viral vectors with reduced capacity to stimulate an adaptive immune response or become invisible to the immune system after delivery of the vector genome.
Number of subjects: 0
Study 17920552 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods to steer the immune response away from cytotoxic responses or induce tolerance to gene therapy products.
Number of subjects: 0
Study 16934684 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (20 kcal/kg) with whey or casein supplement (40 g/day)
Number of subjects: 20
Study 16934684 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (20 kcal/kg)
Number of subjects: 20
Study 14616407 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole (3 mg kg‐1) administered once daily on days 1 and 12, and every 12 h on days 3‐11 (Study A)
Number of subjects: 30
Study 14616407 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole (loading dose 6 mg kg‐1 twice on day 1, then 3 mg kg‐1 twice daily on days 2‐9, and once at 3 mg kg‐1 on day 10) (Study B)
Number of subjects: 30
Study 14616407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study A and Study B)
Number of subjects: 30
Study 10688417 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid group (1 g of methylprednisolone intravenously administered two hours before operation)
Number of subjects: 20
Study 10688417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 20
Study 9005140 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar and cuff shoulder immobilization
Number of subjects: 67
Study 9005140 — intervention group
Group type: COMPARATOR
Intervention: No shoulder immobilization (control)
Number of subjects: 67
Study 1913367 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 9
Study 1913367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6613236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg SIN 1
Number of subjects: 23
Study 6613236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31745601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 1649
Study 26927501 — intervention group
Group type: EXPERIMENTAL
Intervention: NA (5 mg/d) with CEE (0.625 mg/d)
Number of subjects: 50
Study 26927501 — intervention group
Group type: COMPARATOR
Intervention: NA (5 mg/d) with placebo
Number of subjects: 50
Study 26291768 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel with PANVAC (arm A)
Number of subjects: 48
Study 26291768 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone (arm B)
Number of subjects: 48
Study 23870813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 610
Study 23870813 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 610
Study 23870813 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 610
Study 23870813 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous treatment
Number of subjects: 610
Study 23870813 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 610
Study 23870813 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 610
Study 21757823 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP group (100 μg bolus injection of hANP)
Number of subjects: 67
Study 21757823 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (physiological saline injection)
Number of subjects: 67
Study 19242495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per day) - arm B
Number of subjects: 96
Study 19242495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine (9 mg/m² per dose) and cytarabine (500 mg/m² per dose) - arm A
Number of subjects: 96
Study 19242495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 96
Study 16531618 — intervention group
Group type: COMPARATOR
Intervention: Vascular brachytherapy (VBT) with a beta source (n = 201)
Number of subjects: 396
Study 16531618 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent implantation (n = 195)
Number of subjects: 396
Study 15144480 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborative pre‐talk
Number of subjects: 128
Study 15144480 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborative during-talk
Number of subjects: 128
Study 15144480 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborative post-talk
Number of subjects: 128
Study 15144480 — intervention group
Group type: COMPARATOR
Intervention: Empty talk (during the event)
Number of subjects: 128
Study 10895406 — intervention group
Group type: EXPERIMENTAL
Intervention: Men and women of all ages presenting with acute coronary disease
Number of subjects: 1782
Study 10895406 — intervention group
Group type: EXPERIMENTAL
Intervention: Older persons with AMI
Number of subjects: 1782
Study 10895406 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with AMI
Number of subjects: 1782
Study 10895406 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients with unstable angina
Number of subjects: 1782
Study 10895406 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with unstable angina
Number of subjects: 1782
Study 9354205 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-10 (amoxycillin 1000 mg b.d. + clarithromycin 500 mg b.d. + omeprazole 20 mg daily for 10 days)
Number of subjects: 267
Study 9354205 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (clarithromycin 500 mg t.d.s. + omeprazole 40 mg daily for 14 days)
Number of subjects: 267
Study 8225301 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational inpatient family intervention
Number of subjects: 169
Study 8225301 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 169
Study 3161825 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of alpha‐human atrial natriuretic peptide injected intravenously
Number of subjects: 6
Study 3161825 — intervention group
Group type: COMPARATOR
Intervention: Comparison with normotensive volunteers
Number of subjects: 6
Study 31927128 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-model (structural connectome)
Number of subjects: 82
Study 31927128 — intervention group
Group type: COMPARATOR
Intervention: Tract-model (atlas-based tract)
Number of subjects: 82
Study 31927128 — intervention group
Group type: COMPARATOR
Intervention: CV-model (clinical variables model)
Number of subjects: 82
Study 29179027 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 0
Study 29179027 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation
Number of subjects: 0
Study 26241686 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized intraperitoneal ropivacaine (AIR)
Number of subjects: 55
Study 26241686 — intervention group
Group type: COMPARATOR
Intervention: Atomized intraperitoneal saline (AIS)
Number of subjects: 55
Study 26225661 — intervention group
Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 131